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Background
Autism spectrum disorders (ASD) is a collective term 
used to describe neurodevelopmental disorders with a 
pattern of qualitative abnormalities in three functional 
domains: reciprocal social interactions, communication, 
and restrictive interests and/or repetitive behaviors [1]. 
Th   ere is strong evidence that 10 to 15% of ASD cases may 
be etiologically related to known genetic disorders, such 
as fragile X syndrome, tuberous sclerosis complex, and 
Rett syndrome [2,3]. However, the etiology of ASD in 
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the strong male:female gender bias (at least 4:1) [4]. With 
regard to identifying genes associated with idiopathic 
autism, which represents 80 to 90% of ASD cases, a 
number of previous studies have conducted genome-
wide scans to ascertain genetic linkage to, or association 
with, ASD. To date, autism susceptibility loci have been 
identiﬁ   ed on almost every chromosome, especially 
chromo  somes 2q [5], 3q [6], 5p [7], 6q [8], 7q [5,9], 11p 
[7], 16p [5], and 17q [7,10]. No single chromosomal 
location, however, has been found to be highly signiﬁ  cant, 
and no genetic variation or mutation within these regions 
has been found to account for more than 1% of ASD 
cases. Copy number variation has also been associated 
with ASD, and the most recent whole genome scan 
performed by Th   e Autism Consortium (2008) revealed a 
recurrent microdeletion and a reciprocal microdupli-
cation on chromosome 16p11.2 [11]. Moreover, a number 
of publications have demonstrated the relevance of 
particular genes to ASD, and numerous candidate genes 
for autism have been identiﬁ  ed,  including  NLGN3/4 
[12,13],  SHANK3 [14], NRXN1 [15], and CNTNAP2 
(Contactin associated protein-like 2) [16-18]. Interest-
ingly, all of these genes function at the synapse, thereby 
focusing attention on dysregulation of synapse formation 
as a neuropathological mechanism in ASD [19,20]. 
However, studying a single ASD candidate gene at a time 
is not likely to provide a comprehensive explanation of all 
pathophysiological conditions associated with these 
disorders, which are believed to result from dysregulation 
of multiple genes.
To examine global transcriptional changes associated 
with ASD, Hu and colleagues [21] examined diﬀ  erential 
gene expression with DNA microarrays using lympho-
blastoid cell lines (LCLs) from discordant monozygotic 
twins, one co-twin of which was diagnosed with autism 
while the other was not. Th  ey found that a number of 
genes important to nervous system development and 
function were among the most diﬀ  erentially expressed 
genes. Furthermore, these genes could be placed in a rela-
tional gene network centered on inﬂ  ammatory mediators, 
some of which were increased in the autopsied brain tissue 
of autistic patients relative to non-autistic controls (for 
example, IL6) [22]. Inasmuch as mono  zygotic twins share 
the same genotype, the results of this study further 
suggested a role for epigenetic factors in ASD.
MicroRNAs (miRNAs) as well as other factors such as 
DNA methylation and chromatin remodeling are thus 
likely candidates in the epigenetic regulation of gene 
expression. miRNAs are endogenous, single-stranded, 
non-coding RNA molecules of approximately 22 nucleo-
tides in length that negatively and post-trans  crip  tionally 
regulate gene expression. Th   e biogenesis and suppressive 
mechanisms of miRNAs have been comprehensively 
described in many studies [23-27], and include miRNA-
mediated translational repression that may also ulti-
mately lead to degradation of the transcript. miRNAs are 
involved in nervous system development and function 
[28-31]. In addition, disrupted miRNA function has been 
proposed to be associated with a number of neurological 
diseases, such as fragile X syndrome [32-35], schizo-
phrenia [36], and spinal muscular atrophy [37]. Recently, 
two studies have reported diﬀ   erential expression of 
miRNA in ASD, one using LCLs as an experimental 
model [38], and the other interrogating miRNA expres-
sion directly in autistic and nonautistic brain tissues [39]. 
However, neither of these studies demonstrated corre-
lation between the diﬀ  erentially expressed miRNA and 
diﬀ   erential expression of the putative target genes or 
gene products.
We postulated that altered miRNA expression would 
result, in part, in altered expression of its target genes. 
Th   erefore, we employed miRNA microarrays to study the 
miRNA expression proﬁ   les of LCL from male autistic 
case-controls, which included monozygotic twins 
discordant for ASD and their nonautistic siblings as well 
as autistic and unaﬀ   ected siblings. miRNA expression 
proﬁ   ling revealed signiﬁ  cantly  diﬀ  erentially  expressed 
miRNAs whose putative target genes are associated with 
neurological diseases, nervous system development and 
function, as well as other co-morbid disorders associated 
with ASD, such as gastrointestinal, muscular, and inﬂ  am-
matory disorders. Th  e goal of this study was to reveal 
dysregulation in miRNA levels that are inversely 
correlated with altered levels of target genes that, in turn, 
may be associated with the underlying pathophysiology 
of ASD, and to provide a better understanding of the role 
of miRNAs as a post-transcriptional gene regulatory 
mechanism associated with ASD.
Methods
Experimental model and cell culture
LCL derived from peripheral lymphocytes of 14 male 
subjects were obtained from the Autism Genetic Resource 
Exchange (AGRE, Los Angeles, CA, USA). Th  e  subjects 
included three pairs of monozygotic twins discordant for 
diagnosis of autism, a normal sibling for two of the twin 
pairs, two pairs of autistic and unaﬀ  ected siblings, and a 
pair of normal monozygotic twins. Th   ese cell lines had all 
been used previously for gene expression proﬁ  ling [21,40] 
and thus allowed us to compare miRNA expression 
proﬁ  les with mRNA expression levels across the aﬀ  ected 
and control samples from both studies. Th   e frozen cells 
were cultured in L-Glutamine-added RPMI 1640 
(Mediatech Inc., Herndon, VA, USA) with 15% triple-0.1 
m-ﬁ   ltered fetal bovine serum (Atlanta Biologicals, 
Lawrenceville, GA, USA) and 1% penicillin-streptomycin-
amphotericin (Mediatech Inc.).
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Cell and DNA Repository (which contains the AGRE 
samples), cultures were split 1:2 every 3 to 4 days, and cells 
were harvested for miRNA isolation 3 days after a split, 
while the cell lines were in logarithmic growth phase. All 
cell lines were cultured and harvested at the same time 
with the same procedures and reagents to minimize the 
diﬀ  erences in miRNA expression that might occur as a 
result of diﬀ  erent cell and miRNA preparations.
miRNA isolation
LCLs were disrupted in TRIzol Reagent (Invitrogen, 
Carlsbad, CA, USA) and miRNAs were then extracted 
from the TRIzol lysate using the mirVana miRNA 
Isolation Kit (Ambion, Austin, TX, USA) according to the 
manufacturers’ protocols. Brieﬂ   y, ethanol (100%) was 
added to TRIzol-extracted, puriﬁ   ed RNA in water to 
bring the samples to 25% ethanol and the mixture was 
then passed through the mirVana glass-ﬁ  ber ﬁ  lter, which 
allowed passage of small RNA in the ﬁ  ltrate. Ethanol was 
added to the ﬁ  ltrate to increase the ethanol concentration 
to 55%, and the mixture was passed through the second 
glass-ﬁ  ber  ﬁ   lter, which immobilized the small RNAs. 
After washing, the immobilized small RNAs were eluted 
in DNase-RNase-free water (Invitrogen), yielding an 
RNA fraction highly enriched in small RNA species 
(≤200 nucleotides). Th   e concentration of the small RNAs 
in the ﬁ  nal fraction was then measured with a NanoDrop 
1000 spectrophotometer (Th   ermo Fisher Scientiﬁ  c, 
Wilmington, DE, USA). To enable comparison of miRNA 
expression patterns across all of the samples, equal 
amounts of miRNAs from unaﬀ  ected siblings and normal 
control individuals were pooled to make a common 
reference miRNA that was co-hybridized with each 
sample on the miRNA microarray.
miRNA microarray analysis
Custom-printed miRNA microarrays were used to screen 
miRNA expression proﬁ   les of LCLs from autistic and 
normal or undiagnosed individuals. Th   e array slides were 
printed in the Microarray CORE Facility of the National 
Human Genome Research Institute (NHGRI, NIH, 
Bethesda, MD, USA). Th  e complete set of non-coding 
RNAs printed in triplicate on Corning epoxide-coated 
slides (Corning Inc., Corning, NY, USA) is shown in 
Additional ﬁ  le  1,  with the subset of human miRNAs 
shown on the second sheet of the Excel workbook. 
Although the printed arrays also included miRNA from 
rat and mouse species as well as some small nucleolar 
RNAs, these were not considered in our analyses. miRNA 
labeling and microarray hybridization were performed 
using  Ambion’s miRNA Labeling Kit and Bioarray 
Essential Kit, respectively, according to the manufacturer’s 
instructions. Brieﬂ  y, a 20- to 50-nucleotide tail was added 
to the 3’ end of each miRNA in the sample using 
Escherichia coli Poly (A) polymerase. Th  e  amine-
modiﬁ   ed miRNAs were then puriﬁ   ed and coupled to 
amine-reactive NHS-ester CyDye ﬂ  uors  (Amersham 
Biosciences, Piscataway, NJ, USA). A reference design 
was used for microarray hybridization in this study. Th  e 
sample miRNAs were coupled with Cy3, whereas the 
common reference miRNA was coupled with Cy5, and 
two-colored miRNA microarray analyses were carried 
out by co-hybridizing an equal amount of both miRNA 
samples onto one slide.
After hybridization and washing, the microarrays were 
scanned with a ScanArray 5000 ﬂ  uorescence  scanner 
(PerkinElmer, Waltham, MA, USA) and the raw pixel 
intensity images were analyzed using IPLab image process-
ing software package (Scanalytics, Fairfax, VA, USA). Th  e 
program performs statistical methods that have been 
previously described [41] to locate speciﬁ  c miRNAs on the 
array, measure local background for each of them, and 
subtract the respective background from the spot intensity 
value (average of triplicate spots). Besides the background 
subtraction, the IPLab program was also used for within-
array normalization and data ﬁ  ltering. Fluorescence ratios 
within the array were normalized according to a ratio 
distribution method at conﬁ   dence level = 99.00. Th  e 
ﬁ  ltered data from the IPLab program were then uploaded 
into R version 2.6.1 software package to perform array 
normalization across all of the samples based upon 
quantile-quantile (Q-Q) plots, using a procedure known as 
quantile normalization [42]. After normalization, 1,237 
miRNAs were detectable above background.
Assessing signifi  cance of miRNA expression
To identify signiﬁ  cantly diﬀ  erentially expressed miRNA, 
the normalized data were uploaded into the TIGR 
Multiexperiment Viewer (TMeV) 3.1 software package 
[43,44] to perform statistical analyses on the microarray 
data as well as cluster analyses of the diﬀ  erentially 
expressed genes. Pavlidis template matching analyses 
[45] were carried out to identify signiﬁ  cantly diﬀ  erentially 
expressed probes between autistic and control groups (P 
≤0.05). Cluster analyses were performed with the 
signiﬁ  cantly diﬀ  erentially expressed miRNAs using the 
hierarchical cluster analysis program within TMeV, based 
on Euclidean distance using average linkage clustering 
methods. Principal component analysis was further 
employed to reduce the dimensionality of the microarray 
data and display the overall separation of samples from 
autistic and control groups.
Prediction of the potential target genes
Th   e lists of the potential target genes of the diﬀ  erentially 
expressed miRNAs were generated using miRBase [46] 
where the miRanda algorithm is used to scan all available 
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mentarity alignment between the miRNA and the 3’ UTR 
sequences of putative predicted mRNA targets. Th  e 
beneﬁ  t of using this program is that it also provides P-
orthologous-group (P-org) values, which represent 
estimated probability values of the same miRNA family 
binding to multiple transcripts for diﬀ  erent species in an 
orthologous group. Th  e values are calculated from the 
level of sequence conservation between all of the 3’ UTRs 
according to the statistical model previously described 
[47]. Only target sites for which the P-org value was <0.05 
were included to minimize false positive predictions. Th  e 
number of target genes was diﬀ  erent for each miRNA, 
but the range of targets per miRNA was between 600 and 
1,200 protein-coding genes.
Preliminary functional analyses of the potential target genes
Ingenuity Pathway Analysis (IPA) version 6.0 (Ingenuity 
Systems, Redwood City, CA, USA) and Pathway Studio 
version 5 (Ariadne Genomics, Rockville, MD, USA) 
network prediction software were used to identify gene 
networks, biological functions, and canonical pathways 
that might be impacted by dysregulation of the diﬀ  er-
entially expressed miRNAs, using the lists of predicted 
target genes of each diﬀ  erentially expressed miRNA to 
interrogate the gene databases. Th   e Fisher exact test was 
used to identify signiﬁ   cant pathways and functions 
associated with the gene datasets.
miRNA TaqMan qRT-PCR analysis
Among the diﬀ  erentially expressed miRNAs, four brain-
speciﬁ   c or brain-related miRNAs (hsa-miR-219, hsa-
miR-29, hsa-miR-139-5p, and hsa-miR-103) were selected 
for conﬁ  rmation analysis by miRNA TaqMan quantitative 
reverse-transcription PCR (qRT-PCR) assays (Applied 
Biosystems, Foster City, CA, USA). Small nucleolar RNA, 
C/D box 24 (RNU24) was used as an endogenous control 
in all qRT-PCR experiments. According to the Applied 
Biosystems TaqMan MicroRNA Assay protocol, cDNA 
was reverse transcribed from 10 ng of total RNA using 
speciﬁ   c looped miRNA RT primers, which allow for 
speciﬁ   c RT reactions for mature miRNAs only. Th  e 
cDNA was then ampliﬁ  ed by PCR, which uses TaqMan 
minor groove binder probes containing a reporter dye 
(FAM dye) linked to the 5’ end of the probe, a minor 
groove binder at the 3’ end of the probe, and a non-
ﬂ  uorescence quencher at the 3’ end of the probe. Th  e 
design of these probes allows for more accurate measure-
ment of reporter dye contributions than possible with 
conventional ﬂ  uorescence quenchers.
Meta-analysis of gene expression data for these same samples
A meta-analysis was performed to correlate diﬀ  erential 
miRNA expression with gene expression data that had 
previously been obtained by our laboratory using the 
same samples. However, because the discordant twin 
study [21] and that involving aﬀ  ected-unaﬀ  ected sib pairs 
[40] were performed using a diﬀ  erent  experimental 
design for microarray hybridization (that is, direct 
sample comparison on the same array for the twin 
samples and a reference design for the sib-pair analysis 
that involved co-hybridization of each sibling sample 
with Stratagene Universal human reference RNA), the 
expression data from the sib-pair study was reanalyzed in 
order to report diﬀ   erences as log2 expression ratios 
between the aﬀ  ected and unaﬀ  ected siblings, which is the 
expression format used in the twin study. Data ﬁ  ltration 
was performed using TMeV version 3.1 software [43] to 
extract only genes for which expression values were 
present in at least four out of seven comparisons. Th  e 
ﬁ  ltered data were then uploaded into the R statistical 
software package [48] to carry out quantile normali-
zation. After global data distribution and normalization 
of data to the same level to enable comparison of gene 
expression data across the combined set of samples, a 
one-class  t-test analysis was conducted across all log2 
ratios using TMeV, and signiﬁ  cantly  diﬀ  erentially 
expressed genes were identiﬁ  ed as those with P-values 
<0.05. In order to capture the largest number of putative 
target genes of the diﬀ  erentially expressed miRNAs for 
our correlation analysis, we performed the t-test without 
multiple sample correction. Th   e complete list of 
diﬀ  erentially expressed genes is provided in Additional 
ﬁ  le 2.
Correlation between the expression of the target genes 
and the candidate miRNAs
To identify the diﬀ  erentially expressed genes potentially 
regulated by the diﬀ   erentially expressed miRNAs in 
autistic individuals, the overlapping genes between the 
signiﬁ  cant gene list from the one-class t-test (P < 0.05) 
and the list of the potential target genes of all the diﬀ  er-
entially regulated miRNAs were identiﬁ  ed.  Figure  1 
shows a schematic of the procedure used to correlate 
miRNA and putative target genes. To correlate miRNA 
expression with putative target gene expression, the 
average log2 expression ratios of miRNA for autistic 
versus unaﬀ   ected groups were calculated and then 
compared against the average log2 mRNA expression 
ratios for these same groups. Only the target genes that 
were expressed in the opposite direction from that of the 
pertinent miRNAs were extracted for functional analyses. 
Although miRNA often acts as a translational repressor 
in mammalian cells, the targeted mRNA species is often 
delivered to P-bodies, where it is eventually degraded 
[49]. Th   us, we decided to perform pathway analyses only 
on those genes whose mRNA changes were directionally 
opposite to the change in miRNA expression, while 
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potential targets of the diﬀ  erentially expressed miRNA.
Identifi  cation of biological functions disrupted by 
dysregulated target genes
To gain insight into biological functions that may be 
disrupted in ASD as a consequence of altered miRNA 
expression, the diﬀ   erentially expressed genes whose 
transcript levels were inversely correlated with those of 
the diﬀ  erentially expressed miRNAs were uploaded into 
IPA and Pathway Studio network prediction programs 
and the target gene networks were generated. For these 
analyses, a relatively stringent expression level cutoﬀ   of 
log2(ratio) ≥ ±0.4 was used inasmuch as we are typically 
able to conﬁ  rm genes with a log2(ratio) ≥ ±0.3 by qRT-
PCR. Signiﬁ   cant biological functions, canonical path-
ways, and diseases highly represented in the networks 
were identiﬁ  ed using Fisher’s exact test (P < 0.05).
Transfection of pre-miRs and anti-miRs
All transfections were performed using siPORT NeoFX 
Transfection Agent (Applied Biosystems) according to 
the manufacturer’s protocol. Brieﬂ  y, LCLs were counted 
and diluted into 2 × 105 cells/2.3 ml and incubated at 
37°C. A total of 5 μl siPORT NeoFX Transfection Agent 
per transfection condition was diluted and incubated for 
10 minutes at room temperature with 95 μl of the pre-
warmed complete growth media (without antibiotics). 
Hsa-miR-29b pre-miR precursor, hsa-miR-219b anti-miR 
inhibitor, Cy3-labeled pre-miR negative control and the 
Cy3-labeled anti-miR negative control (Applied Bio-
systems, Foster City, CA, USA) were separately diluted to 
a ﬁ  nal small RNA concentration of 30 nM in 100 μl of 
complete growth media. Cell suspensions were overlaid 
onto each of the transfection solutions and mixed gently 
before incubation at 37°C with 5% CO2 for 72 hours. 
Under these conditions, most cells were observed by 
ﬂ   uores  cence microscopy to be transfected with Cy3-
labeled pre-miR and anti-miR negative controls (Addi-
tional ﬁ  le 3), while cytotoxicity, monitored by the MTS 
cell proliferation assay (Promega, Madison, WI, USA) 
was determined to be negligible (Additional ﬁ  le  4). 
Follow  ing the 72-hour incubation, the cells were 
harvested for subsequent analyses.
Microarray data deposition
All data from the DNA microarray and miRNA micro-
array analyses have been deposited in the Gene 
Expression Omnibus (GEO) data repository. Th  e GEO 
accession number for the miRNA data from this study is 
[GEO:GSE21086]. Th   e GEO accession numbers for gene 
expression data for the twin and sib-pair studies are 
[GEO:GSE4187] and [GEO:GSE15451], respectively.
Results
Signifi  cantly diff  erentially expressed miRNAs diff  erentiate 
clinical from non-clinical samples
To identify signiﬁ  cantly diﬀ  erentially expressed miRNAs 
that diﬀ   erentiate clinically discordant individuals, 
normalized miRNA microarray data were uploaded into 
the TMeV program for statistical analysis. Pavlidis tem-
plate matching analysis revealed 43 human miRNAs that 
were signiﬁ  cantly  diﬀ   erentially regulated (P < 0.05) 
between autistic and nonautistic individuals. Th  ese 
miRNAs and their corresponding log2 ratios for autistic 
versus control samples are shown in Table  1. Cluster 
analyses were performed to further determine whether or 
not the expression levels of these miRNAs could 
distinguish between the autistic and control groups. Both 
un  supervised, hierarchical cluster analysis (Figure 2a) and 
supervised, 2-cluster K-means analysis (data not shown) 
revealed complete separation of the autistic and control 
groups based on expression proﬁ  les of the diﬀ  erentially 
expressed miRNAs. Principal component analysis 
(Figure 2b), which was employed to reduce the dimen  sion-
ality of the microarray data, also revealed clear separa  tion 
between autistic individuals and controls based on the 43 
signiﬁ  cant probes, which was also validated by support 
vector machine analysis that demonstrated 100% accuracy 
of class prediction (data not shown).
Biological network prediction of the potential targets 
revealed a strong association with neurological functions 
and other biological pathways involved in ASD
Potential target genes for each of the diﬀ  erentially 
expressed miRNAs were identiﬁ   ed using miRBase 
Figure 1. Schematic fl  ow diagram describing procedures 
used to identify inversely correlated diff  erentially expressed 
putatitve target genes of the diff  erentially expressed miRNAs. 
Tens of thousands of putative target genes are associated with the 
43 diff  erentially expressed miRNAs, some of which are overlapping 
between diff  erent miRNAs. For the correlation analyses, we used all of 
the putative target genes.
41,472 genes
3,905 genes; P-value < 0.05
t-test
1,406 overlapping genes
TIGR40K cDNA Microarray
Potential targets of the 
miRNAs
1,053 genes
Custom MicroRNA Microarray
716 unique human miRNAs
43 miRNA; P-value < 0.05
All putative targets
PTM
miRBase
inverse expression
Putative targets of inversely correlated 
differentially expressed miRNA
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networks and functions in which these target genes are 
involved, the target gene list for each miRNA was 
analyzed using IPA (Table 2). Interestingly, the target 
genes of 35 out of the 43 human miRNA probes (more 
than 80% of the signiﬁ  cantly  diﬀ  erentially  expressed 
miRNAs) were found to be signiﬁ  cantly associated with 
‘neurological functions’ or ‘nervous system development 
and function’ (Fisher’s exact test, P < 0.05).
In addition to gene targets associated with neurological 
functions, it is noteworthy that a number of the 
Table 1. Signifi  cantly diff  erentially expressed human 
miRNAs
Clone ID  miRNA  log2 ratio  P-value
Down-regulated
  SM10801 hsa-miR-182-AS  -1.54  1.44E-03
 hSQ018350  hsa-miR-136  -1.50  2.28E-03
 SM10637  hsa-miR-518a  -1.45  3.52E-03
 hSQ045460  hsa-miR-153-1  -1.41  5.07E-03
 SM11115  hsa-miR-520b  -1.38  6.71E-03
 SM10529  hsa-miR-455  -1.30  1.25E-02
 hHM044864  hsa-miR-326  -1.24  1.95E-02
 SM10553  hsa-miR-199b  -1.23  1.96E-02
 miR211  hsa-miR-211  -1.23  2.04E-02
 hSQ016068  hsa-miR-132  -1.22  2.20E-02
 SM10792  hsa-miR-495  -1.20  2.43E-02
 hSQ025962  hsa-miR-16-2  -1.19  2.54E-02
 hHM044822  hsa-miR-190  -1.18  2.69E-02
 hHM044960  hsa-miR-219  -1.17  2.98E-02
 hHM045056  hsa-miR-148b  -1.16  3.01E-02
 hHM044897  hsa-miR-189  -1.16  3.06E-02
 hHM045063  hsa-miR-133b  -1.13  3.59E-02
 hSQ018899  hsa-miR-106b  -1.11  4.11E-02
 hHM044849  hsa-miR-367  -1.10  4.21E-02
 SM10740  hsa-miR-139  -1.10  4.32E-02
Up-regulated
 hHM044819  hsa-miR-185  1.44  4.04E-03
 hHM044919  hsa-miR-103  1.31  1.20E-02
 hHM044733  hsa-miR-107  1.26  1.68E-02
 hHM044918  hsa-miR-29b  1.24  1.88E-02
 hHM045013  hsa-miR-194  1.22  2.11E-02
 SM10729  hsa-miR-524  1.22  2.21E-02
 hHM044804  hsa-miR-191  1.21  2.23E-02
 SM11334  hsa-miR-376a-AS  1.19  2.53E-02
 SM10789  hsa-miR-451  1.19  2.64E-02
 hHM044971  hsa-miR-23b  1.17  2.95E-02
 miR195  hsa-miR-195  1.16  3.02E-02
 SM10711  hsa-miR-23b  1.16  3.03E-02
 SM10310  hsa-miR-342  1.15  3.24E-02
 SM10644  hsa-miR-23a  1.14  3.36E-02
 hSQ001775  hsa-miR-186  1.14  3.43E-02
 miR25  hsa-miR-25  1.14  3.55E-02
 SM10575  hsa-miR-519c  1.13  3.71E-02
 SM10238  hsa-miR-346  1.12  3.80E-02
 hHM044950  hsa-miR-205  1.12  3.80E-02
 hHM044743  hsa-miR-30c  1.11  3.98E-02
 hSQ027766  hsa-miR-93  1.10  4.18E-02
 hHM045009  hsa-miR-186  1.08  4.67E-02
 hHM044831  hsa-miR-106b  1.08  4.86E-02
Forty-three signifi  cantly diff  erentially expressed human miRNAs were identifi  ed 
by Pavlidis Template Matching (PTM) analysis (P < 0.05). The log2 ratios for all 
miRNAs were calculated from the average of the log2 ratio across all autistic 
samples over the average of the log2 ratio across all control samples.
Figure 2. Hierarchical cluster analysis and principal component 
analysis of signifi  cantly diff  erentially expressed miRNAs from 
the Pavlidis template matching analysis. (a) Unsupervised 
hierarchical cluster analysis of 43 signifi  cantly diff  erentially expressed 
miRNAs between all autistic individuals (red bar) and controls 
(turquoise bar) shows the distinct miRNA expression pattern of the 
two groups (P < 0.05). The individual samples are coded as follows: 
AT, autistic twin; AS, autistic sibling; CT, control, undiagnosed twin; 
CS, control, nonautistic sibling; C_6a/b, nonautistic, monozygotic 
twins a and b. The same numbers following the sample descriptors 
indicate members of the same family. (b) Principal component 
analysis of the samples based on the same set of miRNAs reduces the 
dimensionality of the data and shows the clear separation between 
the autistic individuals (red) and the controls (turquoise).
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Page 6 of 18Table 2. Ingenuity Pathways Analysis biological functions and pathways associated with potential targets for 
signifi  cantly diff  erentially expressed miRNAs
miRNA  Biological functions/pathways of the miRNA targets (P-value) [number of genes]*
hsa-miR-182  N (1.18E-03 to 3.86E-02) [59], E (1.49E-03 to 3.70E-02) [14]
hsa-mir-136  G (1.60E-04 to 3.46E-02) [10], A (6.33E-03) [8], E (3.50E-03 to 3.46E-02) [21]
hsa-miR-518a  N (7.24E-03 to 4.89E-02) [50], E (8.57E-05 to 4.44E-02) [20]
hsa-mir-153-1  N (1.02E-05 to 2.24E-02) [28], G (6.37E-04 to 1.53E-02) [13]
hsa-miR-520b  N (2.66E-03 to 4.44E-02) [15], E (8.13E-04 to 4.44E-02) [28]
hsa-miR-455  N (2.03E-03 to 4.51E-02) [83], E (1.06E-03 to 4.51E-02) [42]
hsa-miR-326  S (6.24E-04 to 3.99E-02) [28]
hsa-miR-199b  N (8.24E-04 to 4.23E-02) [31], E (6.04E-03 to 4.23E-02) [21], S (5.23E-03 to 4.23E-02) [11]
hsa-miR-211  N (7.78E-05 to 2.99E-02) [15], I (6.23E-04 to 2.99E-02) [19]
hsa-mir-132  N (2.01E-03 to 4.48E-02) [19], G (2.01E-03 to 4.48E-02) [23], E (2.01E-03 to 4.48E-02) [28]
hsa-miR-495  N (6.09E-04 to 4.02E-02) [48], G (1.62E-03 to 4.02E-02) [10], E (2.51E-04 to 4.02E-02) [24]
hsa-mir-16-2  N (8.75E-05 to 4.45E-02) [13], E (1.06E-03 to 4.45E-02) [24], S (1.58E-03 to 4.45E-02) [17], Es (4.86E-02) [9]
hsa-miR-190  N (6.63E-04 to 3.86E-02) [39], G (2.15E-03 to 3.86E-02) [12], E (3.83E-04 to 4.15E-02) [25]
hsa-miR-219  N (1.08E-03 to 4.34E-02) [87], E (1.88E-03 to 4.34E-02) [11]
hsa-miR-148b  N (6.54E-04 to 4.63E-02) [27], G (3.81E-04 to 4.63E-02) [27]
hsa-miR-189  N (1.57E-03 to 3.76E-02) [23}, E (1.57E-03 to 3.76E-02) [19]
hsa-miR-133b  E (7.84E-04 to 2.56E-02) [17]
hsa-mir-106b  N (1.37E-03 to 4.41E-02) [21], G (1.01E-02 to 4.23E-02) [33], I (1.54E-03 to 4.38E-02) [18]
hsa-miR-367  N (1.35E-03 to 4.37E-02) [20], G (1.33E-03 to 4.37E-02) [11] 
hsa-miR-139  G (1.37E-03 to 4.02E-02) [19], E (1.61E-03 to 4.02E-02) [21]
hsa-miR-186  N (9.62E-04 to 3.11E-02) [27], E (2.83E-03 to 3.11E-02) [14], S (9.62E-04 to 3.11E-02) [17], Es (1.82E-02) [8]
hsa-mir-93  N (2.67E-04 to 4.33E-02) [36], I (4.47E-04 to 4.33E-02) [35]
hsa-miR-30c  N (9.85E-05 to 4.21E-02) [40], E (3.31E-04 to 4.21E-02) [25]
hsa-miR-205  N (1.40E-03 to 3.75E-02) [9], S (1.19E-04 to 3.75E-02) [23]
hsa-miR-346  I (8.61E-04 to 3.03E-02) [56]
hsa-miR-519c  G (7.42E-04 to 4.76E-02) [81], N (6.58E-03 to 4.71E-02) [25]
hsa-miR-25  N (1.04E-04 to 3.61E-02) [39], Es (3.95E-02) [8]
hsa-mir-186  N (9.62E-04 to 3.11E-02) [27], E (2.83E-03 to 3.11E-02) [14], S (9.62E-04 to 3.11E-02) [17], Es (1.82E-02) [8]
hsa-miR-23a  N (1.69E-03 to 4.11E-02) [81], S (8.70E-04 to 4.11E-02) [62]
hsa-miR-342  N (6.49E-04 to 4.11E-02) [15], E (2.13E-03 to 4.11E-02) [12], S (6.49E-04 to 4.11E-02) [15]
hsa-miR-23b  N (4.31E-05 to 4.01E-02) [87], S (3.71E-03 to 4.01E-02) [60], E (4.68E-03 to 4.01E-02) [20]
hsa-miR-195  N (4.59E-03 to 4.04E-02) [74], Es (1.12E-02) [10]
hsa-miR-23b  N (4.31E-05 to 4.01E-02) [87], S (3.71E-03 to 4.01E-02) [60], E (4.68E-03 to 4.01E-02) [20]
hsa-miR-451  S (2.99E-04 to 2.43E-02) [29] 
hsa-miR-376a  N (1.62E-03 to 3.88E-02) [23], E (1.62E-03 to 3.10E-02) [10], S (1.17E-04 to 4.02E-02) [32], C (4.71E-03) [5]
hsa-miR-191  N (2.53E-04 to 4.62E-02) [34], E (1.87E-03 to 3.93E-02) [12]
hsa-miR-524-3p  N (3.44E-04 to 4.47E-02) [66]
hsa-miR-194  N (8.47E-03 to 3.86E-02) [24]
hsa-miR-29b  S (1.97E-05 to 2.91E-02) [41], C (1.63E-03) [6]
hsa-miR-107  G (4.81E-04 to 4.13E-02) [46], E (1.27E-03 to 4.13E-02), N (1.70E-03 to 4.13E-02) [16]
hsa-miR-103  G (1.31E-03 to 4.27E-02) [49], E (2.01E-04 to 4.27E-02), S (3.03E-03 to 4.27E-02) [23], N (1.82E-03 to 4.27E-2) [35]
hsa-miR-185  N (8.16E-04 to 3.75E-02) [26]
IPA analysis of potential target genes for each of the signifi  cantly diff  erentially expressed miRNAs revealed biological functions and pathways associated with the 
target genes. P-values calculated from Fisher’s exact test for each function are listed in parenthesis; the number of genes involved in each biological function or 
pathway is listed in square brackets. The functions are described as: A, androgen and estrogen metabolism; C, circadian rhythm signaling; E, embryonic development; 
Es, estrogen receptor signaling; G, gastrointestinal diseases/digestive system development and functions; I, infl  ammatory diseases; N, neurological diseases/nervous 
system development and functions; S, skeletal and muscular disorders/skeletal and muscular system development and functions.
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Page 7 of 18diﬀ   erentially expressed miRNAs also target genes 
involved in co-morbid disorders associated with ASD, 
such as muscular and gastrointestinal diseases [50-58]. 
Target genes of 13 miRNAs (30%) signiﬁ  cantly  dys-
regulated in autistic individuals were associated with 
skeletal and muscular diseases as well as skeletal and 
muscular development or function. Target genes for 12 
signiﬁ  cantly dysregulated miRNAs (28%) were associated 
with gastrointestinal disorders, development, and func-
tion, as well as hepatic system disease, hepatic ﬁ  brosis, 
and hepatic cholestasis (P < 0.05). It is interesting to note 
that these disorders are among the most signiﬁ  cant 
biological functions and pathways enriched within the 
dataset of target genes, inasmuch as ASD individuals are 
frequently found to have co-morbid diagnoses involving 
muscle dysfunction (for example, muscular dystrophy, 
muscle weakness, and hypotonia) and digestive disorders 
that aﬀ  ect absorption and metabolism.
Another interesting biological function associated with 
the miRNA gene targets is steroid hormone metabolism. 
More than 11% (5 out of 43) of the diﬀ  erentially expressed 
miRNAs showed an association with androgen and 
estrogen metabolism, as well as with estrogen receptor 
signaling (P < 0.05). Moreover, IPA also showed that 
target genes for two of the most up-regulated miRNAs - 
hsa-miR-376a and hsa-miR-29b - were signiﬁ  cantly 
associated with circadian rhythm signaling (Fisher’s exact 
test, P = 4.71E-03 and 1.63E-03, respectively).
Quantitative TaqMan RT-PCR confi  rmation of selected miRNAs
MicroRNA TaqMan quantitative RT-PCR (qRT-PCR) 
analyses were performed to conﬁ  rm the miRNA expres-
sion data of four miRNAs known to be associated with 
brain development and function. Hsa-miR-29b and hsa-
miR-219 are known to be brain-speciﬁ  c, while hsa-miR-
139-5p is highly enriched in brain [59-61]. Although not 
speciﬁ   c to the brain, hsa-miR-103 is highly expressed 
during corticogenesis [59,62], suggesting an important 
role in brain development and function. Expression levels 
of all four brain-associated miRNAs from these analyses 
were correlated with miRNA microarray data (Figure 3).
Correspondence between diff  erentially expressed putative 
target genes and the diff  erentially regulated miRNAs
To examine the possibility that changes in speciﬁ  c 
miRNAs could result in corresponding changes in the 
expression levels of the putative target genes, diﬀ  er-
entially expressed genes from previous cDNA micro  array 
analyses of the same LCLs used in this study [21,40] were 
compared with the potential target genes of the 
diﬀ  erentially expressed miRNAs. Of the 3,905 diﬀ  eren-
tially expressed genes between the autistic and control 
groups, 1,406 (36%) were found to be putative targets of 
the diﬀ  erentially expressed miRNA, with 1,053 (27%) of 
these genes exhibiting changes inversely correlated with 
the respective miRNA changes. Th  ese percentages of 
target genes predicted to be regulated by the miRNA 
identiﬁ   ed in this study are within the range of the 
approxi  mately 10 to 60% of protein-coding genes that are 
estimated to be regulated by miRNA [63-65]. Although 
translational repression is the main mechanism of 
suppres  sion by miRNA in mammalian cells, the sup-
pressed target mRNA often eventually is degraded in 
P-bodies [49], thus leading to the expected decreases in 
transcript levels observed here. A recent study further 
conﬁ   rms the eﬀ   ect of miRNA on suppressing target 
mRNA levels [66].
To increase the stringency of the pathway analyses, an 
expression level cutoﬀ   of log2(ratio) ≥ ±0.4 was applied to 
the diﬀ  erentially expressed genes, which reduced the list 
of potential gene targets to 94 genes. IPA analysis of this 
set of genes (Table 3) revealed a number of genes signiﬁ  -
cantly involved in neurological disease (P = 1.38E-03 to 
1.89E-02). Inﬂ  ammatory diseases, which have also been 
associated with ASD [22], were found to be signiﬁ  cantly 
associated with the diﬀ   erentially expressed potential 
target genes (P = 2.51E-03 to 2.11E-02). It is interesting to 
note that lipid metabolism is a cellular function that is a 
potential target of miRNA regulation. Th   e top canonical 
pathways implicated by the target genes were nitric oxide 
signaling (P = 1.07E-02), vascular endothelial growth 
factor (VEGF) signaling (P = 1.47E-02), and amyotrophic 
lateral sclerosis signaling (P = 1.88E-02).
Figure 3. Results of TaqMan miRNA qRT-PCR analyses of four 
brain-associated miRNAs (hsa-miR-219-5p, hsa-miR-139-5p, 
hsa-miR-29b, and hsa-miR-103) in autistic and control 
lymphoblastoid cell lines. Expression levels of selected miRNAs 
associated with brain development from TaqMan qRT-PCR analyses 
confi  rm data obtained by miRNA microarrays. Green bars, qRT-
PCR data; orange bars, DNA microarray data. Error bars represent 
standard errors associated with miRNA Taqman qRT-PCR or miRNA 
microarray analyses (hsa-miR-219-5p/hsa-miR-29b/hsa-miR-103, n = 5 
case-control pairs; hsa-miR-139-5p, n = 4 pairs).
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Page 8 of 18Network prediction of the diff  erentially expressed potential 
target genes of the diff  erentially expressed miRNAs in ASD
Th  e diﬀ   erentially expressed potential miRNA targets 
were analyzed with Pathway Studio 5 to identify the 
possible relationships among the target genes and their 
associated functions (Figure 4). Interestingly, the pathway 
generated by Pathway Studio revealed relationships 
between the potential targets of the miRNAs and autism, 
as well as other neurological functions and disorders 
previously found to be impacted or associated with ASD, 
such as memory, regulation of synapses, synaptic 
plasticity, muscle disease, muscular dystrophy, and 
muscle strength [50,51,67].
Validation of miRNA targets
Two brain-speciﬁ  c miRNAs (hsa-miR-29b and hsa-miR-
219-5p), whose diﬀ   erential expression in ASD was 
conﬁ  rmed by TaqMan miRNA qRT-PCR analyses, were 
selected for miRNA target validation. Among putative 
target genes of these miRNAs are Inhibitor of DNA 
binding 3 (ID3), which is a target of miR-29b, and Polo-
like kinase 2 (PLK2), a target of miR-219-5p. ID3 and 
PLK2 have been associated with circadian rhythm 
signaling and modulation of synapses, respectively 
[68-71], and both biological mechanisms have been 
implicated in ASD [12,14-16,72-79]. To examine whether 
the overexpression of hsa-miR-29b and the suppression 
of hsa-miR-219-5p may be responsible for the respective 
decrease in ID3 and increase in PLK2 transcript levels, 
LCLs derived from three nonautistic individuals were 
transfected with hsa-miR-29b pre-miR precursor and 
hsa-miR-219b anti-miR inhibitor, respectively, to increase 
hsa-miR-29b and decrease hsa-miR-219-5p activity in the 
cells. qRT-PCR analyses of the transfected cells revealed 
the down-regulation of the ID3 gene in the LCLs 
transfected with hsa-miR-29b pre-miR precursor, and the 
up-regulation of the PLK2 gene in the LCLs transfected 
with hsa-miR-219b anti-miR inhibitor (Figure 5). Th  ese 
results suggest that ID3 and PLK2 are targets of hsa-miR-
29b and hsa-miR-219-5p, respectively. Furthermore, 
most of the paired comparisons exhibit opposite changes 
in miRNA and mRNA target expression levels, suggesting 
that PLK2 and ID3 are in vivo targets of the respective 
miRNA (Table 4).
Table 3. Predicted biological functions from Ingenuity Pathways Analysis
     Number
   P-value of  genes  Genes
Diseases and disorders
  Neurological disease  1.38E-03 to 1.89E-02  8  UCHL1, ATF3, NDP, TUBB2C, KIF1B, TUBB2A, MST1, BCL2
  Infl  ammatory disease  2.51E-03 to 2.11E-02  16  IL6ST, ADM, TUBB2C, IL32, PIK3R1, TUBB2A, EIF1, ALOX5AP, MMP10, 
       DUSP2, BCL2, GNAI2, HSPA8, FUT8, LDLR, AHNAK
  Skeletal and muscular disorders  2.71E-03 to 1.89E-02  16  IL6ST, ADM, COL6A2, TUBB2C, IL32, TUBB2A, ALOX5AP, MMP10, 
       LARGE, DUSP2, BCL2, GNAI2, HSPA8, CEP290, BMI1, AHNAK
Molecular and cellular functions
  Lipid metabolism  1.19E-04 to 2.51E-02  13  ADM, IL6ST, ABCG5, ABHD5, IL32, PIK3R1, ALOX5AP, BCL2, GNAI2, 
       IFRD1, LDLR, PRKAR2B, PITPNC1
  Molecular transport  1.19E-04 to 2.51E-02  12  IL6ST, IFRD1, HSPA8, GNAI2, ABHD5, ABCG5, LDLR, PIK3R1, IL32, 
       PITPNC1, ALOX5AP, BCL2
  Small molecule biochemistry  1.19E-04 to 2.51E-02  17  IL6ST, ADM, AMPD3, ABCG5, ABHD5, PIK3R1, ASS1, IL32, ALOX5AP, 
       BCL2, IFRD1, GNAI2, BCAT1, LDLR, PITPNC1, GOT1, GLDC
  Cellular development  1.32E-04 to 2.42E-02  13  IL6ST, ATF3, PIK3R1, ID3, BCL2, IGLL1, IFRD1, ELF3, BMI1, PRKAR2B, 
       PLK2, LAMA1, PLAC8
  Cell death  2.36E-04 to 1.89E-02  14  IL6ST, ADM, ATF3, DDIT4, PIK3R1, NCK1, PSIP1, SH3BP5, ID3, BCL2, 
       PRKAR2B, BMI1, PLK2, PLAC8
Canonical pathways
  Nitric oxide signaling  1.07E-02  3/90  CACNA1E, PRKAR2B, PIK3R1
 VEGF  signaling  1.47E-02  3/92 PIK3R1, EIF1, BCL2
  Amyotrophic lateral sclerosis signaling  1.88E-02  3/108  CACNA1E, PIK3R1, BCL2
Toxicity list
  Hormone receptor regulated cholesterol metabolism  4.96E-02  1/8  LDLR
IPA of signifi  cant disorders, molecular and cellular functions, canonical pathways, and toxicity genes that are strongly associated with 94 diff  erentially expressed 
potential target genes of the miRNAs (log2 ratio ≥ ±0.4). The Fisher’s exact P-values and the number of genes for each top biological function are listed. VEGF, vascular 
endothelial growth factor.
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miRNA expression in autism spectrum disorders
In this study, we demonstrate the diﬀ  erential expression 
of 43 miRNA species in LCLs from individuals with ASD 
relative to controls (Table 1), 16 of which are brain-
speciﬁ   c, brain-related, or involved in neural diﬀ  eren-
tiation [59-62]. Although the total number of samples in 
this study is modest, the use of discordant monozygotic 
twins and sibling case-controls oﬀ   ers the ability to 
identify diﬀ  erences in miRNA against the same or closely 
related genotype, which is an advantage in investigations 
of epigenetic mechanisms contributing to autism. We 
have previously used this strategy in ﬁ  rst identifying gene 
expression diﬀ  erences in these same monozygotic twins 
[21] and sibling case-controls [40], and then validated our 
initial ﬁ  ndings with a larger study involving 116 unrelated 
case-controls [77]. Here, we further utilize the original 
gene expression data of these same samples to 
demon  strate that diﬀ   erentially expressed miRNA can 
account for approximately 36% of the diﬀ  erentially 
expressed transcripts [21,40], thus implicating miRNA as 
a potent regulator of gene expression in ASD. Functional 
analyses of the putative gene targets that show inverse 
correlation with the expression of miRNA reveal numer-
ous processes relevant to or associated with ASD that are 
potentially regulated by the diﬀ  erentially  expressed 
miRNA (Table 2, Figure 4). Th  ese processes include 
embry  onic develop  ment, synaptic development and 
func  tion, circadian rhythm signaling, inﬂ  ammation, 
androgen metabolism, and digestive functions, mirroring 
the major ﬁ   ndings of our gene expression analyses 
[21,40,77]. Signiﬁ  cantly, we verify inverse changes in the 
levels of putative target genes of two of the altered brain-
speciﬁ   c miRNAs through the use of anti-miRs (for 
knockdown) and pre-miRs (for overexpression) 
(Figure 5).
Figure 4. Relationships between diff  erentially expressed miRNAs, putative target genes, and functions. Network and pathway analysis 
using Pathway Studio 5 shows the relationships among the signifi  cantly diff  erentially expressed miRNAs, potential target genes (expression cutoff   
log2 ratio ≥ ±0.4), and biological functions and disorders implicated by the diff  erentially expressed target genes. Up-regulated genes and miRNAs 
are in red; down-regulated genes and miRNAs are in green.
miRNA
Putative target genes
Disrupted biological functions and disorders
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Page 10 of 18To date, only two other studies have conducted miRNA 
expression proﬁ  ling of autistic individuals. Talebizadeh 
and colleagues [38] evaluated the global expression of 
470 known human miRNAs using LCLs derived from six 
autistic individuals and six sex- and age-matched controls 
by miRNA microarray assays. Of these 470 miRNAs, they 
found nine that were signiﬁ  cantly diﬀ  erentially expressed 
in the autistic samples. Th   ree of the nine miRNAs were 
replicated in our study, with similar up-regulation of 
miR-23a and miR-23b, but down-regulation of miR-132. 
Although we have no speciﬁ   c explanation for this 
contrasting result for miR-132, diﬀ  erences between our 
study and that of Talebizadeh et al. [38] include our use 
of related samples (that is, co-twins/siblings) as controls, 
a custom-printed rather than commercial platform, and 
the restriction of our study to male subjects. Additional 
analyses are thus required to further explain the 
diﬀ  erences in miRNA expression data between these two 
studies on LCLs.
Abu-Elneel et al. [39] investigated the expression of 466 
human miRNAs in postmortem cerebellar cortex tissue 
of 13 autistic individuals using multiplex quantitative 
PCR and found 13 down-regulated and 16 up-regulated 
miRNAs. Interestingly, the up-regulation of miR-23a and 
down-regulation of miR-106b reported in the autistic 
cerebellar cortex were also found in our study using 
LCLs. Predicted potential target genes of miR-23a were 
found to be associated with neurological diseases and 
skeletal and muscular system development and functions, 
whereas those of miR-106b were associated with neuro-
logical diseases, inﬂ  ammatory diseases, and gastro  intes-
tinal diseases (Table 2). Th  ese ﬁ   ndings support the 
Table 4. Comparison of miRNA and mRNA expression levels for discordant twins and sib pairs for miR-219 and its target, 
PLK2, and for miR-29b and its target, ID3
miRNA  (target)  A361/C360 A809/C810 A809/C813  A2369/C2368  A2369/C2357  A366/C365  A2769/C2772 Average
miR-219 (PLK2)  -1.447 (0.414)  -1.089 (0.147)  -2.330 (NA)  -2.390 (NA)  -0.175 (NA)  0.398 (0.314)  -1.176 (0.456)  -1.173 (0.333)
miR-29b (ID3)  0.585 (-0.406)  1.720 (-0.187)  1.287 (-0.574)  0.395 (-0.603)  1.315 (0.070)  2.939 (-0.152)  0.061 (-0.233)  1.186 (-0.298)
The fi  rst three columns are log2 ratios for discordant monozygotic twins, while the last four columns are ratios for sib-pair comparisons. NA, no expression ratio 
obtained for this gene because an intensity value for either the autistic or control sample was missing.
Figure 5. Validation of miRNA targets. Three LCLs from non-autistic individuals were transfected with hsa-miR-29b pre-miR precursor, 
hsa-miR-219b anti-miR inhibitor, pre-miR negative control, or anti-miR negative control. At 72 hours after transfection, qRT-PCR analyses were 
conducted to determine expression of PLK2 and ID3 genes in the pre-miR/anti-miR-transfected LCLs (red), compared to respective pre-miR/anti-
miR negative controls (navy). (a,b) Expression of PLK2 was signifi  cantly increased in the LCLs transfected with anti-miR-219-5p (a), whereas ID3 
expression was signifi  cantly decreased in pre-miR-29b-transfected LCLs (b). The error bars show the standard error among the technical replicates. 
*P < 0.05.
(a) (b)
*
* *
*
*
*
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Page 11 of 18hypothesis that miRNA dysregulation in peripheral blood 
cells can reﬂ  ect at least some miRNA alterations occur-
ring in the brain, thus lending support to the use of LCLs 
as a surrogate tissue to study miRNA expression in 
individuals with ASD.
Brain-related miRNAs are diff  erentially expressed in LCLs 
from ASD patients
Our earlier studies proﬁ  ling gene expression in LCLs from 
monozygotic twins and siblings discordant for diagnosis of 
autism and unrelated autistic case-controls reveal the 
diﬀ  erential expression of hundreds to thousands of genes 
[21,40,77], suggesting that higher level epigenetic gene 
regulatory mechanisms are involved in ASD. Th  e  present 
study provides further insight into the post-transcriptional 
gene regulatory network asso  ciated with ASD by identi-
fying diﬀ  erential miRNA expres  sion as one mechanism for 
the diﬀ   erential gene expression associated with ASD. 
Interestingly, at least 16 of these miRNAs have been 
previously reported by Sempere and colleagues [59] to be 
brain-speciﬁ   c, brain-enriched, or induced by neuronal 
diﬀ  erentiation. Krichev  sky and colleaques [62] reported 
signiﬁ   cant changes in the expression of nine miRNAs 
during brain development; one of these miRNAs 
(miR-103) was also signiﬁ  cantly diﬀ  erentially expressed in 
our study. Th   us, the diﬀ  erential expression of these brain-
related miRNAs in LCLs suggests that gene expression 
diﬀ  erences pre  viously observed in LCLs [21,40,77] may 
reﬂ  ect similar changes in the brain, possibly due to global 
or system-wide dysregulation of miRNA expression.
Biological functions associated with the confi  rmed miRNAs 
and their target genes
Using miRNA TaqMan qRT-PCR, we conﬁ  rmed  four 
diﬀ  erentially expressed miRNAs (hsa-miR-219-5p, hsa-
miR-139-5p, hsa-miR-29b, and hsa-miR-103) previously 
reported to be associated with the brain [59-62]. Of the 
conﬁ  rmed miRNAs, we observed a signiﬁ  cant decrease 
in brain-speciﬁ  c hsa-miR-219, which is associated with 
circadian rhythm and N-methyl-D-aspartate (NMDA) 
glutamate receptor signaling, both of which have been 
implicated in ASD [72-77,80,81]. In particular, Kocerha 
and colleagues [82] found that disruption of NMDA 
receptor signaling resulted in decreased levels of miR-219 
in mice. Hypofunction of NMDA receptor signaling has 
been associated with a number of neurological disorders, 
including autism [83-85], attention deﬁ  cit hyperactivity 
disorder [86,87], and schizophrenia [88]. One of the 
putative target genes whose expression was conﬁ  rmed to 
be inversely correlated with hsa-miR-219 expression is 
PLK2 (Figure 4), a serine/threonine kinase expressed in 
the brain [89] that participates in regulation of cell cycle 
progression [90] and homeostatic plasticity of hippocampal 
neurons [69,70]. A recent study found that PLK2 was 
induced during prolonged epileptiform activity, and was 
required for the activity-dependent reduction in mem-
brane excitability of pyramidal neurons, suggesting 
PLK2’s role in preventing escalating potentiation and in 
maintaining synapses in a plastic state [71]. PLK2 
induction in hippocampal neurons resulted in weakening 
of synapses through phosphorylation and degradation of 
post-synaptic spine-associated Rap GTPase-activating 
protein (SPAR), a regulator of actin dynamics and den-
dritic spine morphology [69,71], leading to loss of mature 
dendritic spines and synapses [91,92]. Over-expression of 
PLK2 in individuals with ASD due to decreased 
hsa-miR-219 levels as observed in this study (Figure 5, 
Table 4) may thus lead to global reduction in synaptic 
strength and neuronal excitability, which could be 
partially responsible for the synaptic dysfunction impli-
cated in ASD.
Another conﬁ  rmed brain-speciﬁ  c miRNA diﬀ  erentially 
expressed in individuals with ASD is hsa-miR-29b. 
Besides its conﬁ  rmed  target, ID3 (Figure 5), which is 
involved in regulating the biological clock (see below), 
other target genes that show expression levels inversely 
correlated with the over-expression of this miRNA 
include  COL6A2 (Collagen, type VI, alpha 2), CLIC1 
(Chloride intracellular channel 1), ARPC5 (Actin related 
protein 2/3 complex, subunit 5, 16kDa), and KIF26b 
(Kinesin family member 26B). Interestingly, a number of 
mutations in COL6A2 have been observed in muscular 
disorders, including Bethlem myopathy [93-95] and 
Ullrich congenital muscular dystrophy [94,96-98]. Muta-
tion in the COL6A2 gene results in decreased COL6A2 
transcript, leading to disruption of collagen formation 
and stability, which results in decreased muscle strength 
[93]. A number of motor impairments and muscular dis-
orders, including muscular dystrophy, hypotonia, and 
muscle weakness, are observed in individuals with ASD 
[50,99,100]. It is therefore interesting to postulate that 
suppression of COL6A2 as a result of up-regulated hsa-
miR-29b may be one of the genetic mechanisms under-
lying muscular disorders and motor impairments 
frequently observed in individuals with ASD.
Among brain-enriched miRNAs [59], hsa-miR-139-5p 
was selected for conﬁ   rmation analysis using miRNA 
TaqMan qRT-PCR assay. Although the precise targets in 
brain are not known, one of its putative targets (myo-
megalin or PDE4DIP (Phosphodiesterase 4D interacting 
protein)) is a homolog of brain-enriched CDK5RAP2 
(CDK5 regulatory subunit associated protein 2), a gene 
that regulates brain size [101-104], which has been shown 
to be abnormal in ASD [105-119]. Interestingly, this 
miRNA has been shown to be involved in prion-induced 
neurodegeneration [120].
Two of the most up-regulated miRNAs, miR-103 and 
miR-107 (Table 1), have been reported to be paralogous 
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human organs, with the highest concentrations occurring 
in brain tissue [121]. Furthermore, miR-103 was 
demonstrated to change during corticogenesis in mice 
[62]. Although the speciﬁ   c targets of miR-103/107 in 
brain are unknown, these miRNAs are known to be 
associated with lipid metabolism [121], and in fact reside 
within introns of the pantothenate kinase (PANK) genes, 
which catalyze the biosynthesis of Coenzyme A, a critical 
component in fatty acid biosynthesis and oxidation. It 
should be noted that, while PANK was not found to be 
among the signiﬁ  cantly diﬀ  erentially expressed genes in 
this study, it was found to be increased in ASD and in the 
same direction as miR-103/107 in our previous study of a 
larger cohort of 31 autistic individuals with severe 
language impairment and 29 controls [77]. Aside from 
the association of PANK mutations and a neuro  degenera-
tive (Hallervorden-Spatz) disease [122,123], alterations in 
lipid and fatty acid metabolism are also known to be 
associated with ASD. Vancassel and colleagues [124] 
examined the levels of phospholipid fatty acids in the 
plasma of individuals with ASD compared to controls 
with mental retardation and found signiﬁ  cant reductions 
in docosahexaenoic acid (22:6n-3) levels in autistic 
individuals, resulting in signiﬁ  cantly lower levels of total 
n-3 polyunsaturated fatty acids. Th  e dysregulation of 
miR-103/7 may therefore contribute to abnormal lipid 
and fatty acid metabolism in ASD.
miRNAs regulating circadian rhythm are signifi  cantly 
dysregulated in ASD
Recently, dysregulation of circadian rhythm has been 
considered as a mechanism for impairments in neuro-
logical and other functions (for example, sleep, digestive) 
in ASD [72-77]. In particular, the circadian rhythm (or 
‘clock’) genes have been posited to underlie social timing 
deﬁ  cits associated with autism [72], as well as lead to the 
sleep disorders frequently observed in ASD [125,126]. 
Bourgeron [75] also proposed an important role for 
circadian rhythm with respect to regulation of synaptic 
genes (NLGN3 (Neuroligin 3), NLGN4 (Neuroligin 4), 
NRXN1 (Neurexin 1), and SHANK3 (SH3 and multiple 
ankyrin repeat domains 3)), thus aﬀ  ecting susceptibility 
to ASD. Our large-scale genomic study also found strong 
support for an association between ASD and circadian 
rhythm dysfunction [77]. Interestingly, as many as 15 
circadian rhythm genes, including AANAT (Arylalkyl-
amine-N-acetyltransferase), BHLBH2 (Class B basic 
helix-loop-helix protein 2), CRY1 (Cryptochrome 1 
(photolyase-like)), NPAS2 (Neuronal PAS domain protein 
2), PER1 (Period homolog 1), PER3 (Period homolog 3), 
and  DPYD (Dihydropyrimidine dehydrogenase), were 
diﬀ   erentially expressed exclusively in the most severe 
phenotype of ASD, which was characterized by severe 
language impairment [77,127]. It is interesting to note 
that two of the most signiﬁ  cantly down-regulated miRNAs 
(miR-219 and miR-132) in individuals with ASD have 
been reported to be involved in modulating the master 
circadian clock located in the suprachiasmatic nucleus 
[128-131]. Speciﬁ  cally,  brain-speciﬁ   c miR-219 was a 
target of the master circadian regulator CLOCK and 
BMAL1 (Brain and muscle ARNT-like 1) complex, exhi-
bited robust circadian rhythm expression, and ﬁ  ne-tuned 
the length of the circadian period in mice [130,131]. It is 
relevant, therefore, that we demonstrate that PLK2, 
which is involved in circadian rhythm signaling, is a 
target of miR-219 (Figure 5).
Functional analyses of putative target genes using IPA 
(Table 2) also showed that other miRNAs (hsa-miR-29b 
and hsa-miR-376a) are signiﬁ   cantly associated with 
circadian rhythm signaling, with hsa-miR-29b targeting 
the ID3 gene, which might be important for entrainment 
and operation of the mammalian circadian system 
through ID3 interaction with CLOCK and BMAL1 [68]. 
Signiﬁ   cantly, we show that hsa-miR-29b pre-miR pre-
cursor results in the down-regulation of ID3 transcript. 
ID3 is also a neuronal target of MeCP2 (Methyl CpG 
binding protein 2), which is the causative gene for Rett 
syndrome [132]. Other putative targets of brain-speciﬁ  c 
hsa-miR-29b are genes known to interact in the 
regulation of the biological clock, including ARNTL (Aryl 
hydrocarbon receptor nuclear translocator-like; BMAL1), 
ATF2 (Activating transcription factor 2), DUSP2 (Dual 
speciﬁ  city phosphatase 2), PER1, PER3, and VIP (Vaso-
active intestinal peptide). Although only DUSP2 was 
found to be diﬀ   erentially expressed in the current 
analysis, it is interesting to note that our recent large-
scale gene expression study of LCLs from over 100 
unrelated case-controls found signiﬁ   cant decreases in 
PER1 and PER3 transcript levels in individuals with the 
most severe phenotype of ASD [77]. However, further 
experimental studies are required to determine whether 
or not the over-expression of hsa-miR-29b results in the 
suppression of these two PER genes.
Target genes of miRNAs involved in functions and 
processes associated with ASD
To obtain more insight into the biological functions 
regulated by each of the diﬀ  erentially  expressed 
miRNAs, the potential target genes of each miRNA 
were predicted in silico and uploaded into IPA network 
prediction software. For most miRNAs, target genes 
were predicted to be involved in neurological disease 
and nervous system development and function on the 
basis of gene enrichment within the dataset (Table 2). 
Th  is  ﬁ  nding suggests that the signiﬁ  cantly diﬀ  erentially 
expressed miRNAs may lead to post-transcriptional 
dysregulation of target genes that, in turn, leads to the 
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patho physiology.
Th  e dysregulation of these speciﬁ  c miRNAs may also 
potentially impact other physiological functions. Besides 
the neurological functions, almost half of the diﬀ  er  en-
tially expressed miRNAs targeted a number of genes 
involved in gastrointestinal disorders and hepatic 
diseases, which have been found in approximately 50% of 
individuals with ASD [133,134]. Our ﬁ  ndings  thus 
provide a plausible explanation for some of the systemic 
eﬀ   ects observed in ASD that aﬀ   ect other organs in 
addition to the nervous system.
Steroid hormones have been suggested to be involved 
in the etiology or susceptibility to ASD [135,136]. In 
particular, previous studies have reported elevated 
androgen levels in the serum of autistic individuals, 
including females [135,136], and we have recently 
reported changes in genes in LCLs that correlated with 
increases in testosterone [40,77]. Androgens and estro-
gens are known to participate in synaptic plasticity in the 
brain of rats. Whereas estrogens have been found to take 
part in synaptic plasticity in the hippocampus of female 
rats [137], androgens can modulate that function in both 
male and female rats [138]. Within this context, it is note-
worthy that four of the diﬀ  erentially expressed miRNAs 
(miR-16, miR-186, miR-25, and miR-195) target genes 
participating in estrogen receptor signaling. miR-136, 
which was one of the most down-regulated miRNAs 
found among all ﬁ  ve ASD samples, is also associated with 
androgen and estrogen metabolism.
miRNAs are known to act through translational 
repression [23-27]. However, the repressed transcripts 
are often degraded in P-bodies, ultimately leading to 
reduced transcript levels for a particular miRNA-
repressed gene [49]. Th  is inverse correlation between 
miRNA and target gene transcript levels is further 
suggested by the observed inverse correlation between 
miRNA ‘host’ genes and the miRNA target transcripts 
using a novel analysis called HOCTAR (for ‘host gene 
oppositely correlated targets’) [66]. Th   us, an increase in a 
particular miRNA is likely to lead to decreased transcript 
levels of target genes and vice versa. However, inverse 
correlation of miRNA and target mRNA levels is not 
necessarily observed. Nevertheless, comparing the 
miRNA expression data obtained by the present study 
with data obtained by our previous cDNA microarray 
analysis of these same samples reveals that the direction 
of change for roughly 27% of the diﬀ  erentially expressed 
genes was inversely correlated with that of the respective 
potentially regulatory miRNAs. Relational gene networks 
constructed using computational network prediction 
tools show that the inversely correlated target genes of 
the signiﬁ  cantly  diﬀ   erentially expressed miRNAs are 
linked to autism as well as to co-morbid disorders 
frequently reported in many autistic individuals (Figure 3). 
For example, a number of genes in the network are linked 
to synaptic function, such as regulation of synapse, 
synaptic plasticity, and synaptic transmission. Synaptic 
plasticity has been comprehensively described in the 
context of fragile X syndrome and linked to autism [139]. 
FMRP (Fragile X mental retardation protein), the key 
protein missing in fragile X syndrome, is an RNA binding 
and transport protein that regulates the translation of 
many other proteins important for synaptic plasticity, 
including neuroligins 3 and 4 and SHANK, all of which 
have been previously associated with autism 
[12,13,139,140]. Muscular dystrophy and muscle disease 
are also known to be among the co-morbid disorders 
frequently found in autism [99]. Th  us, putative target 
genes of the diﬀ  erentially expressed miRNAs identiﬁ  ed in 
this study can be associated with both neurological as 
well as co-morbid features of ASD.
Although the major behavioral symptoms of ASD 
appear to be of neurological origin, the prevalence of 
gastrointestinal abnormalities, hypotonia, and immune 
disorders in individuals with ASD have led some 
researchers to view ASD more as a systems disorder that 
is a result of gene and environment interactions. Th  us, 
several recent studies, including three from our labora-
tory [21,40,77], have used LCLs as a surrogate experi-
mental model to better understand the pathobiology of 
ASD as well as to identify peripheral biomarkers of ASD 
for diagnostic purposes [21,38,40,77,127,141,142]. In 
particular, our previous study of monozygotic twins 
discordant for diagnosis or severity of autism revealed 
diﬀ  erentially expressed genes with known neurological 
functions of potential relevance to autism [21]. Because 
identical twins share the same genotype, this study 
suggested the involvement of epigenetic factors in the 
regulation of gene expression in ASD. Furthermore, the 
global scale of the observed changes in gene expression 
suggested the operation of ‘master switches’ that can 
activate or suppress multiple genes at once. Non-coding 
RNAs, including miRNAs, are potential epigenetic 
regulators of gene expression and can operate in this 
fashion [24,143-146].
Conclusions
Our miRNA expression proﬁ  ling study of LCLs derived 
from individuals with ASD, their discordant monozygotic 
co-twins, and/or their unaﬀ  ected siblings reveals a set of 
signiﬁ  cantly  diﬀ   erentially expressed miRNAs whose 
target genes are associated with neurological diseases 
and functions. Moreover, by integrating and correlating 
both miRNA and gene expression data from the same 
samples, we take a systems biology approach to reducing 
the total number of relevant targets for further study as 
candidate ASD genes. Finally, the signiﬁ  cant diﬀ  erential 
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detected in LCLs may reﬂ  ect systemic changes under-
pinning ASD that give rise to neuropathological 
conditions and, moreover, support the use of LCLs as a 
surrogate tissue to study miRNA expression in ASD.
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